Hyde IQ vs Hyde N-Bar: A Comparison of Disposable Vapes

Sep.08.2022
Hyde IQ vs Hyde N-Bar: A Comparison of Disposable Vapes
Hyde Vape offers top-tier disposable and rechargeable e-cigarettes, each with unique features such as battery indicators and flavor options.

Today, the e-cigarette industry is one of the fastest-growing industries. This is especially true as e-cigarettes have been popular in the market for a long time. Among the different varieties available, disposable e-cigarettes have become the perfect choice for users due to their portability and design. The Hyde Vape brand is one of the best brands that offers disposable e-cigarettes.

 

The two most popular choices from Hyde vape are the Hyde IQ Disposable Vape Pen 5000 Puffs and the Hyde N-Bar 4500 Puffs Rechargeable. However, these electronic cigarette devices have more or less similar functions, making it difficult to choose the better device.

 

For your convenience, we will assist you in understanding the difference between the two in this article.

 

In an attempt to differentiate between Hyde IQ and Hyde N-Bar, we have identified various parameters. We aim to provide a clearer understanding of both product categories.

 

Number of inhalations/suctions.

 

Although both of these electronic cigarette devices are among the best and most durable disposable products on the market, they differ in the number of puffs they can provide.

 

The Hyde IQ can provide an excellent vaping experience with approximately 5000 puffs from a single charge, while the Hyde N-Bar rechargeable vape lasts for about 4500 puffs.

 

Although Hyde N-Bar boasts a 4500 puff count, which is relatively high compared to other disposable e-cigarettes on the market, it falls behind Hyde IQ.

 

Therefore, in terms of maximum suction times, the Hyde IQ performs slightly better than the Hyde N-Bar.

 

Battery indicator light.

 

Regarding battery capacity and lifespan, both Hyde IQ and Hyde N-Bar have rechargeable batteries and are convenient for USB charging.

 

However, the Hyde IQ disposable Vape Pen 5000 Puffs comes equipped with a unique battery indicator light.

 

This innovative battery features indicator lights that display three signals: red when the battery is only at 1-16% capacity, orange when it is at approximately 16-30% capacity, and green when it is at 30-100% capacity.

 

For vapers, this is very convenient. Therefore, in this aspect, Hyde IQ is stealing the show with its innovation.

 

Electronic cigarette liquid or e-liquid.

 

When comparing disposable electronic cigarettes, one important factor to consider is the e-liquid. This type of liquid is contained in various cartridges and contains propylene glycol and nicotine.

 

The Hyde N Bar 4500 Puffs is a rechargeable vape with a pre-filled electronic liquid capacity of 10 milliliters. The liquid contains approximately 5% nicotine.

 

Alternatively, the Hyde IQ comes with a vape juice capacity of 8 milliliters. However, its nicotine content is similar to that of the Hyde N-Bar, at 5%.

 

Therefore, the nominal edge of Hyde N-Bar in terms of e-liquid is approximately 2 milliliters.

 

However, despite the difference in the amount of e-liquid between the two, Hyde IQ produces more puffs and lasts for 1-2 days longer. Therefore, it is clear that the efficiency of Hyde N-Bar is lower than that of Hyde IQ.

 

When it comes to popular choices in e-cigarettes, both Hyde IQ and Hyde N Bar offer a variety of flavors.

 

The Hyde IQ disposable Vape Pen 5000 comes in 20 different flavors including watermelon soda, cranberry orange soda, pink burst, and lemon drop. Each flavor is unique and exciting.

 

On the other hand, Hyde N-Bar offers over 20 flavors including popular choices such as aloe grape, banana and cream, minty O's, peach mango watermelon, Caribbean cola, and tropical flavors.

 

Therefore, in terms of taste, both electronic cigarette devices are comparable.

 

Conclusion

 

The Hyde IQ disposable Vape Pen with 5000 puffs and the Hyde N-Bar 4500 Puffs Rechargeable Vape are two of the best disposable e-cigarettes available in the market. While we have highlighted some distinguishing parameters, it is ultimately up to you to make the best judgment.

 

Statement:

 

This article is compiled from third-party information and is only intended for industry-related communication and learning purposes.

 

This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of the article's content. The translation of this article is intended only for industry-related exchange and research purposes.

 

Due to limitations in translation ability, the article may not fully express the same meaning as the original. Please refer to the original article for accuracy.

 

2FIRSTS aligns fully with the Chinese government when it comes to any domestic, Hong Kong, Macau, Taiwan, or foreign related statements and positions.

 

The compilation of information is the copyright of the original media and author. If there is any infringement, please contact us for removal.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
German Bundestag Passes Tobacco Tax Hikes: Vape Liquid Duty to Reach €0.44/ml, Heated Tobacco Taxes to Rise and Cigarettes Seen Near €12 a Pack
German Bundestag Passes Tobacco Tax Hikes: Vape Liquid Duty to Reach €0.44/ml, Heated Tobacco Taxes to Rise and Cigarettes Seen Near €12 a Pack
Germany's Bundestag passed amendments to the Tobacco Tax Act on October 15, 2026, setting out annual excise tax increases from 2027 through 2030 for e-cigarette liquids, heated tobacco, cigarettes and other tobacco products. Under the Finance Committee's amended bill, duty on qualifying e-liquids will rise from €0.32/ml in 2026 to €0.44/ml in 2030, an increase of 37.5%. Heated tobacco will retain its tax calculation based on 80% of the corresponding cigarette excise duty. The average price of a 20-cigarette pack is projected to approach €12 by 2030, with some brands potentially reaching €14. The legislation is projected to generate approximately €11.8 billion in additional tax revenue over four years and remains subject to further legislative procedures.
Regulations
Oct.19
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09